Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacific Biosciences of California, Inc. - Common Stock (NQ:PACB)

1.170 -0.030 (-2.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacific Biosciences of California, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. (NASDAQ: AZTA) rose on Tuesday after the company reported better-than-expected fourth-quarter... 
Via Benzinga
Topics Stocks
Exposures US Equities
Cathie Wood Continues On Roku Shares Selling Spree After Company's Q3 Revenue Jump — Ark Sells $21.1M Of Stock
Via Benzinga
Cathie Wood's Ark Invest Purchases $9.5M Worth Of Robinhood Shares, Downsizes Holdings Of Grayscale Bitcoin Investment Trust
Via Benzinga
Analyst Expectations for Pacific Biosciences's Future
Via Benzinga
Pacific Biosciences's Earnings Outlook
Via Benzinga
7 Analysts Have This to Say About Pacific Biosciences
Via Benzinga
5 Analysts Have This to Say About Pacific Biosciences
Via Benzinga
Earnings Scheduled For October 30, 2023
Companies Reporting Before The Bell • HSBC Holdings (NYSE:HSBC) is likely to report earnings for its third quarter. 
Via Benzinga
Analyst Expectations for Pacific Biosciences's Future
Via Benzinga
Cathie Wood Just Added $5 Million of This Stock After It Had a Steep Pullback. Is It a No-Brainer Buy?
This innovator is targeting a huge, rapidly growing market. 
Via The Motley Fool
Cathie Wood Goes Shopping For Stock of Jack Dorsey's Block — Ark Invest Bolsters Portfolio With Archer Aviation, CRISPR Shares
Via Benzinga
Cathie Wood's Ark Invest Sells Over $25M Worth Of Tesla Shares Amid Boost In Price
Via Benzinga
Cathie Wood's Buying These 3 Stocks Hand Over Fist
A drugmaker, a gene sequencer, and a streaming business all made deep impressions on Ark Invest's stock-picking team. 
Via The Motley Fool
Rising Fuel Costs Lead To Win For Energy, Cathie Wood's Biotech Play Loses Big - ETF Winners And Losers: Medium-Cap Returns
We performed a screening of medium-cap ETFs, defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns... 
Via Benzinga
Topics ETFs
The Latest Analyst Ratings for Pacific Biosciences
Via Benzinga
Analyst Ratings for Pacific Biosciences
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The growth-focused money manager is making moves, with her ETFs beating the market again in 2023 after terrible returns the two previous years. 
Via The Motley Fool
Where Pacific Biosciences Stands With Analysts
Via Benzinga
Expert Ratings for Pacific Biosciences
Via Benzinga
Palantir Post Q2 Earnings Share Price Dip Doesn't Deter Cathie Wood — Ark Invest Buys $14M Worth Of Shares
Via Benzinga
Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports
Via Benzinga
PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care
Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms 
From GeneDx Holdings Corp.; PacBio
Via GlobeNewswire
Cathie Wood's Ark Invest Acquires $5.5M of Robinhood Shares Following Platform's First Profitable Quarter
Via Benzinga
Thoughts For Thursday: Back From The Holiday With Caution
Caution is perhaps what was reflected in yesterday's back from the holiday trading. One there is the question of upcoming Fed action and second there is the visit of Secretary Yellen to China. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023
Via Benzinga
Market Mixes It Up With A Broad Rally
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
Time To Play Small Cap Life Science Stocks
The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
Via Benzinga
Something Happened In Biotech Last Week
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.